CLINICAL TRIALS PROFILE FOR OXYCODONE HYDROCHLORIDE AND IBUPROFEN

505(b)(2) Clinical Trials for OXYCODONE HYDROCHLORIDE AND IBUPROFEN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00245375 ↗	A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	N/A	2005-01-01	Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC	NCT00245375 ↗	A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery	Completed	Nova Scotia Health Authority	N/A	2005-01-01	Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC	NCT02929589 ↗	Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy	Suspended	Mike O'Callaghan Federal Hospital	Phase 3	2018-07-05	This is a prospective, randomized, double-blinded, and placebo-controlled trial comparing oxycodone/acetaminophen prescribed with or without ibuprofen for pain control following open unilateral inguinal hernia repair, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued. The patients will not be allowed to continue any over-the-counter pain medications, such as ibuprofen, naproxen, or acetaminophen containing medications, that were not prescribed by the investigators during this study. Patients not receiving Ibuprofen will be given a placebo pill composed of corn starch. The placebo pill will be formulated into the same shape, size and color as the ibuprofen capsule. Neither the investigators nor the research subjects will know if the subject is receiving a placebo versus Ibuprofen. The subjects will complete pain level and medication diaries, and will be followed for 2 months after their surgery. The research aims to discover the appropriate amount of opioid medication to prescribe to patients undergoing an elective open inguinal hernia repair, and reduce the total opioid dose needed by utilizing ibuprofen in combination. The investigators expect that the subjects who take ibuprofen will use less oxycodone/acetaminophen, and have comparable or lower mean pain levels. This could contribute to reducing the surplus opioids prescribed by physicians after surgery, which can lead to opioid use disorders. This particular procedure is common in men, and the findings have the potential to decrease the symptoms and pain of Active Duty members and DoD beneficiaries who undergo an inguinal hernia repair, and are at risk for prescription drug abuse or dependence.
OTC	NCT02929589 ↗	Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy	Suspended	Mike O'Callaghan Military Hospital	Phase 3	2018-07-05	This is a prospective, randomized, double-blinded, and placebo-controlled trial comparing oxycodone/acetaminophen prescribed with or without ibuprofen for pain control following open unilateral inguinal hernia repair, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued. The patients will not be allowed to continue any over-the-counter pain medications, such as ibuprofen, naproxen, or acetaminophen containing medications, that were not prescribed by the investigators during this study. Patients not receiving Ibuprofen will be given a placebo pill composed of corn starch. The placebo pill will be formulated into the same shape, size and color as the ibuprofen capsule. Neither the investigators nor the research subjects will know if the subject is receiving a placebo versus Ibuprofen. The subjects will complete pain level and medication diaries, and will be followed for 2 months after their surgery. The research aims to discover the appropriate amount of opioid medication to prescribe to patients undergoing an elective open inguinal hernia repair, and reduce the total opioid dose needed by utilizing ibuprofen in combination. The investigators expect that the subjects who take ibuprofen will use less oxycodone/acetaminophen, and have comparable or lower mean pain levels. This could contribute to reducing the surplus opioids prescribed by physicians after surgery, which can lead to opioid use disorders. This particular procedure is common in men, and the findings have the potential to decrease the symptoms and pain of Active Duty members and DoD beneficiaries who undergo an inguinal hernia repair, and are at risk for prescription drug abuse or dependence.

All Clinical Trials for OXYCODONE HYDROCHLORIDE AND IBUPROFEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00245375 ↗	A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	N/A	2005-01-01	Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
NCT00245375 ↗	A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery	Completed	Nova Scotia Health Authority	N/A	2005-01-01	Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
NCT00312221 ↗	Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain	Terminated	Purdue Pharma LP	Phase 3	2004-04-01	The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (20 mg) in comparison to the buprenorphine transdermal system (5 mg) and oxycodone immediate release in subjects with moderate to severe osteoarthritis pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen, immediate release oxycodone) will be provided to all subjects in addition to study drug.
NCT00313014 ↗	Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain	Terminated	Purdue Pharma LP	Phase 3	2004-02-01	The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in subjects with moderate to severe low back pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will be provided to all subjects in addition to study drug.

Clinical Trial Conditions for OXYCODONE HYDROCHLORIDE AND IBUPROFEN

Condition Name

Condition Name for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Intervention	Trials
Pain	12
Pain, Postoperative	10
Postoperative Pain	6
Acute Pain	4

Condition MeSH

Condition MeSH for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Intervention	Trials
Pain, Postoperative	27
Acute Pain	6
Agnosia	5
Osteoarthritis	3

Clinical Trial Locations for OXYCODONE HYDROCHLORIDE AND IBUPROFEN

Trials by Country

Trials by Country for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Location	Trials
United States	178
Canada	8
Norway	2
France	2
China	1

Trials by US State

Trials by US State for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Location	Trials
California	16
New York	12
Pennsylvania	10
Texas	8
Missouri	7

Clinical Trial Progress for OXYCODONE HYDROCHLORIDE AND IBUPROFEN

Clinical Trial Phase

Clinical Trial Phase for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Clinical Trial Phase	Trials
PHASE4	4
PHASE3	2
PHASE2	2

Clinical Trial Status

Clinical Trial Status for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Clinical Trial Phase	Trials
COMPLETED	32
Recruiting	16
Not yet recruiting	10

Clinical Trial Sponsors for OXYCODONE HYDROCHLORIDE AND IBUPROFEN

Sponsor Name

Sponsor Name for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Sponsor	Trials
Montefiore Medical Center	5
Purdue Pharma LP	4
Stanford University	4

Sponsor Type

Sponsor Type for OXYCODONE HYDROCHLORIDE AND IBUPROFEN
Sponsor	Trials
Other	97
Industry	17
U.S. Fed	2

Oxycodone Hydrochloride and Ibuprofen: clinical trials update, market analysis and near-term projections

Last updated: May 23, 2026

Oxycodone hydrochloride plus ibuprofen is marketed in the US as a fixed-dose combination analgesic (historically under the brand name Combunox; exact commercial status can vary by market and authorization year). Public disclosures typically focus on prescribing, pharmacovigilance, and label safety rather than new late-stage efficacy trials for the combination itself.

What is the latest clinical trials update for oxycodone hydrochloride and ibuprofen?

Bottom line: Public registries show limited visibility of new late-stage (Phase 3) comparative efficacy trials for the combination product versus ongoing or completed studies that are often older, registry-specific, or focused on formulation, PK/BE, or safety in targeted populations.

What phases have been most active historically?

• Phase 2–3 clinical development for the oxycodone/ibuprofen combination is largely earlier in the product lifecycle, with later activity in many jurisdictions shifting to:
  • post-authorization safety follow-up
  • observational studies and pharmacovigilance reporting
  • label updates and real-world effectiveness or safety analyses

Are new Phase 3 trials being run now?

Featured trial updates for this exact fixed-dose combination tend to be sparse. Where activity appears, it is often:

• PK/BE studies for specific dosage strengths or changes in manufacturing
• pain management studies using the combination as part of multimodal regimens
• safety studies (GI risk, opioid-related adverse events, misuse/abuse surveillance)

What endpoints dominate ongoing or completed studies?

Common endpoints in the combination’s historical and current study ecosystem include:

• pain intensity change (e.g., sum of pain intensity differences, time to meaningful pain relief)
• rescue medication use
• functional outcomes for acute pain settings
• safety: GI adverse events, renal effects, opioid-related events (sedation, constipation, respiratory depression risk), and abuse-related signals

How big is the market for oxycodone plus ibuprofen and who buys it?

Bottom line: The combination sits in the acute and perioperative pain segment, competing with generic NSAIDs, opioid monotherapy, and other opioid/NSAID combinations where permitted and supported by local formularies.

Where does demand concentrate?

• Short-duration acute pain use cases (including post-injury and some outpatient pain)
• Stepwise prescribing patterns where clinicians balance opioid potency with NSAID efficacy and opioid-sparing goals

Which channels matter most?

• Hospital formularies and outpatient pain pathways are the main demand drivers
• Managed care and pharmacy benefit design affect utilization
• Generic availability of oxycodone and ibuprofen as separate agents typically pressures combination pricing and volume

How does combination prescribing compare with separate products?

Clinicians generally weigh:

• dosing convenience vs. titration flexibility
• NSAID contraindications (GI bleed risk, renal impairment, concomitant anticoagulants)
• opioid contraindications and risk mitigation requirements
• payer incentives for generic separation

What is the competitive landscape for oxycodone hydrochloride plus ibuprofen?

Bottom line: The competitive set is not limited to other fixed-dose opioid/NSAID combinations. It includes:

• generic ibuprofen and generic oxycodone used as separate components
• other opioid formulations (immediate-release and extended-release where clinically appropriate)
• NSAID alternatives (naproxen, diclofenac, ketorolac where eligible)
• multimodal regimens that reduce opioid exposure (acetaminophen + NSAID, topical agents, adjuvants)

What substitution threats are largest?

• Generic separate dosing: ibuprofen + oxycodone prescribed on individualized schedules
• Formulary substitution: preference for non-fixed combinations or non-opioid NSAID strategies
• Safety-driven substitution: high GI-risk or opioid-risk patients move away from the fixed combination

Which companies typically compete in adjacent segments?

The combination’s market impact is usually mediated by:

• generic manufacturers of oxycodone HCl and ibuprofen
• branded and generic opioid product holders
• large generic distributors that can support low acquisition cost and formulary penetration

What does the patent and exclusivity landscape imply for new entry?

Bottom line: Fixed-dose combination products typically have a patent estate that is already mature if the product has long market history. Near-term entry risks are usually tied to:

• whether any remaining formulation, method-of-use, or dosing regimen patents exist
• whether regulatory exclusivities (if any) are still active, typically expiring long ago in an established combo

What patent types usually protect opioid/NSAID fixed combinations?

• formulation patents (composition, particle form, dissolution profile)
• manufacturing/process patents
• method-of-use patents (clinical use claims, dosing schedules, safety windows)
• polymorph or stability patents (less common for combination generics once established)

How does exclusivity affect timeline?

For established combos:

• regulatory exclusivity typically expires before meaningful new entrants can challenge
• remaining patents, if any, determine whether authorized generic entry or ANDA-type entry can proceed

How does the FDA regulatory status of oxycodone plus ibuprofen shape availability?

Bottom line: FDA status controls US labeling and whether products can be marketed as direct replacements or require specific risk controls.

What is the most likely FDA pathway context?

• The combination is usually marketed through established approvals for fixed-dose combos rather than new NDA pathways, given lifecycle maturity.
• Any current product availability depends on whether specific strengths and label versions remain actively marketed and distributed.

What label and risk controls matter clinically?

• opioid risks (boxed warning context, REMS implications if applicable to the product’s opioid component)
• NSAID risks (GI bleeding, ulceration risk, renal effects)
• contraindications: NSAID hypersensitivity, active GI bleeding, significant renal impairment, and other class cautions
• drug interaction cautions (anticoagulants, antiplatelets, corticosteroids, CYP and opioid metabolite considerations)

What market projections apply over the next 3–5 years?

Bottom line: A stable-to-declining volume trajectory is the most typical pattern for mature fixed-dose opioid/NSAID combinations in the face of:

• generic separation of components
• payer pressure toward lower-cost alternatives
• tighter opioid prescribing controls and risk management practices

Base-case demand dynamics

• volume: pressured by generic oxycodone + ibuprofen prescribing on individualized schedules
• price: down due to generic competition or channel negotiation
• utilization: constrained by NSAID safety limits and opioid risk controls

Bull-case and bear-case drivers

• Bull-case: payer support for fixed-dose convenience when clinically appropriate; favorable guideline alignment in acute pain pathways
• Bear-case: increased restrictive opioid policies, NSAID contraindication recognition, and continued preference for non-opioid multimodal regimens

Near-term forecast shape (qualitative)

• Year 1–2: incremental erosion from generic substitution and formulary switching
• Year 3–5: continued stabilization at a lower share unless a renewed clinical, regulatory, or formulation repositioning occurs

How strong is the patent estate for the combination product?

Bottom line: For an established oxycodone/ibuprofen fixed-dose product, the patent estate is typically in late-life. Real protective strength usually comes from:

• any still-active formulation/manufacturing patents
• any remaining method-of-use claims with enforceable jurisdiction coverage
• any pending patent disputes that delay generic entry in select routes

What should be the practical litigation view?

• If multiple patents have expired, generic entry becomes more feasible for permitted dosage strengths
• If any active combination or dosing claims remain, they can block entry for specific strengths or require carve-outs

What generic entry risks exist for oxycodone plus ibuprofen?

Bottom line: The main risk is authorized or unauthorized replacement by separate generics, which does not require IP freedom for the exact fixed combination. For the fixed combination itself, entry risk depends on the still-active patent set and any FDA-listed exclusivities.

What entry modes typically matter?

• generic fixed-dose versions if approved and if IP barriers are cleared
• pharmacy substitution with separate generics (often the dominant practical threat)
• market shrinkage as payers and prescribers move to lower-cost regimens

How does oxycodone plus ibuprofen compare with other opioid/NSAID strategies?

Bottom line: The fixed-dose combination competes on adherence and opioid-sparing appeal but faces substitution pressure from flexible dosing regimens.

Comparison axes that affect adoption

• dosing flexibility: ability to titrate opioid dose independently
• NSAID constraints: contraindication heterogeneity among patients
• GI and renal risk management: monitoring burden may increase for fixed dosing
• clinician workflow: prescriptions, quantity, and refill patterns

Market outlook by region: where growth or erosion is most likely?

Bottom line: US and other high-regulatory-complexity markets typically show:

• early generic erosion
• continued pressure from opioid stewardship policies
• stronger demand only where fixed-dose convenience is tightly embedded in pathways

Geographic differences that matter

• reimbursement practices and formulary strictness
• local opioid guideline interpretation
• availability of alternative fixed-dose products or non-opioid analgesic standards

Key commercial indicators to track for projection accuracy

Bottom line: Near-term market movement for the combination is most sensitive to a small set of measurable KPIs:

• US prescription volume and NBRx (national prescription trends for the fixed combination)
• payer formulary position (preferred vs non-preferred)
• average unit price and net price after rebates
• opioid prescribing rates in outpatient care (as a macro proxy for demand)
• NSAID utilization trends and safety alerts that change clinician behavior

Key Takeaways

• Public visibility of new late-stage clinical trials for the oxycodone hydrochloride plus ibuprofen fixed-dose combination appears limited; most activity is typically safety, PK/BE, and registry/observational work.
• Market share is pressured by the ease of prescribing separate generics (ibuprofen + oxycodone) and by ongoing opioid stewardship and risk management policies.
• Over the next 3–5 years, the combination is most likely to show volume erosion and pricing pressure unless payers and clinicians continue to place the fixed-dose option in specific acute pain pathways.
• Patent and exclusivity effects are usually secondary in mature combination products compared with generic substitution of components.

FAQs

1. Is oxycodone hydrochloride and ibuprofen still prescribed for acute pain in the US?
   Use depends on local formulary position, prescriber opioid practices, and NSAID contraindication screening.

2. Do clinical trials exist for newer dosing schedules of oxycodone/ibuprofen combinations?
   When present, they are usually regimen- or formulation-focused rather than broad new Phase 3 efficacy programs.

3. What safety risks drive payer restrictions on opioid/NSAID combinations?
   GI bleeding/ulcer risk from the NSAID component and opioid adverse-event risk (sedation, respiratory depression risk, constipation) are the primary drivers.

4. How do opioid prescribing guidelines affect fixed-dose opioid/NSAID combinations?
   Guideline tightening tends to reduce opioid volume overall, which lowers addressable demand unless the combination is explicitly embedded in multimodal acute pain pathways.

5. What is the most direct threat to the fixed-dose combination’s market share?
   Generic separation: prescribing oxycodone and ibuprofen as separate products with individualized titration and lower net cost.

References

1. ClinicalTrials.gov. (n.d.). Oxycodone hydrochloride and ibuprofen search results. https://clinicaltrials.gov/
2. US FDA. (n.d.). Drug labeling and safety information for opioid and NSAID products. https://www.fda.gov/drugs